Anti-epileptogenic clinical trial designs in epilepsy: issues and options - Test2 - elhamkhani - TriplyDB

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

http://www.wikidata.org/entity/Q27027689

about

The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.2014 Epilepsy Benchmarks: Progress and Opportunities.2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression.Are big potassium-type Ca(2+)-activated potassium channels a viable target for the treatment of epilepsy?Disease modification in epilepsy: from animal models to clinical applications.Methodological issues associated with clinical trials in epilepsy.Prevention of Epilepsy: Issues and Innovations.A combination of NMDA and AMPA receptor antagonists retards granule cell dispersion and epileptogenesis in a model of acquired epilepsy Novel concepts in epileptogenesis and its prevention.Commonalities in epileptogenic processes from different acute brain insults: Do they translate?Epileptiform activity in traumatic brain injury predicts post-traumatic epilepsy.

P2860

Q30576758-3A1E4C21-8D62-4A03-99AE-6A0418341AC6 Q37021049-DE8F4DAE-3CB0-46D6-9D4B-3B5FECD14EE4 Q37021058-DEA12AC7-0028-49FD-9070-D02D37E203A7 Q38404580-0011FFAA-6E24-4D34-A586-6A63FF37D901 Q38450069-65660CA5-B442-4335-BB82-A7F48510DA5A Q38656392-016ED64B-BBE8-413A-80B6-F1A7C2BC3C3D Q38954567-86F9DDC9-447B-4A70-8147-2A365814A11D Q41917625-85D7AABF-60B6-43B5-9C27-309F0D30EA88 Q42336430-CC58164B-B361-4BDF-A660-A347C9946484 Q47653416-99E6C1C0-8455-48B2-95A8-9A62D862A2E3 Q52656284-3BE6588C-DF02-4B13-BD75-0701C9010A3C

P2860

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

http://www.wikidata.org/entity/Q27027689

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@ast

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@en

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@nl

type

label

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@ast

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@en

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@nl

prefLabel

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@ast

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@en

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@nl

P1433

Q27027689-0B36511B-5104-4032-98E3-CC4E42EC22A1

P1476

Q27027689-94FD157D-2AAD-4874-99B5-9E747BFCAE87

P2093

Q27027689-E1886F4C-1FF8-40AA-B2E4-AC9839A75728

Q27027689-FAB3B878-4546-4F6E-8B02-1F9AAA2BCC23

Q27027689-FC919A35-DA66-4C96-A187-8503D9B89796

P2860

Q27027689-008F9717-5390-4AF8-B47B-BF2043F70F38

Q27027689-00B4BE8A-C647-4B88-958B-168CD376828A

Q27027689-00D7D00A-4935-4C1D-9C4F-842FF47F05EA

Q27027689-062551EE-7BC1-454C-AF66-080B92932696

Q27027689-0A4DD8FA-3CF8-4D58-96A6-6C0653D42033

Q27027689-0D6EBF41-AD43-4FF5-AA91-63108843ECD5

Q27027689-0EB315C5-557E-4697-A74D-0F528A6F9ACF

Q27027689-108F8CE1-59EA-43F4-BD32-BBE739678D97

Q27027689-1EE37A5D-11FC-4F3C-A54D-C6FA519E3BE2

Q27027689-249C2BCF-F74F-4E57-B2AF-138CEB3FEE88

P2888

Q27027689-7CCFC82C-5497-4D6B-8740-E4BE1E1A9899

P304

Q27027689-B6424B9B-DAC2-4BE4-9368-7B9FE85843B6

P31

Q27027689-4F49C60A-7C67-49F6-BC21-4FFCFAFF61D8

P356

Q27027689-F36735E2-A4A5-425F-ABFC-21480FC4E2BE

P407

Q27027689-4C69B79B-EDAB-4300-9BA1-76CDE5E8CC5B

P433

Q27027689-F518E73F-A46B-4AFF-B270-17EE1572AB8B

P478

Q27027689-B63373F3-C2BA-4BEB-B747-4F81FD6D04E1

P577

Q27027689-566E0F83-2100-4B02-8094-32412DB5C1B8

P5875

Q27027689-5C06C876-42AB-41BF-BCD1-FF44F364DC18

P6179

Q27027689-17110455-8F20-4E71-88E6-D7B4C87563E2

P698

Q27027689-2D8E308F-E40A-45B4-BA95-0ED2A72BF5D2

P932

Q27027689-DD176288-89E2-473C-A44E-05C5BEF6587B

P356

S13311-013-0252-Z

P1433

Neurotherapeutics

P1476

Anti-epileptogenic clinical trial designs in epilepsy: issues and options

@en

P2093

Daniel Friedman

http://www.w3.org/2001/XMLSchema#string

Dieter Schmidt

http://www.w3.org/2001/XMLSchema#string

Marc A. Dichter

http://www.w3.org/2001/XMLSchema#string

P2860

The treatment of depressive disorders in epilepsy: what all neurologists should know

Issues related to development of antiepileptogenic therapies.

Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy

Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma.

Early identification of refractory epilepsy

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Update of the stroke therapy academic industry roundtable preclinical recommendations

Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers.

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

On the incidence of fits and mental retardation in tuberous sclerosis

P2888

s13311-013-0252-z

P304

401-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13311-013-0252-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259720990

http://www.w3.org/2001/XMLSchema#string

P6179

1045485620

http://www.w3.org/2001/XMLSchema#string

P698

24420312

http://www.w3.org/2001/XMLSchema#string

P932

3996121

http://www.w3.org/2001/XMLSchema#string